sorafenib has been researched along with tolvaptan in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 967 | 172 | 786 |
| Protein | Taxonomy | sorafenib (IC50) | tolvaptan (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 9.99 | |
| Vasopressin V2 receptor | Homo sapiens (human) | 0.1486 | |
| Vasopressin V1a receptor | Homo sapiens (human) | 0.351 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Sas, KM | 1 |
1 review(s) available for sorafenib and tolvaptan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for sorafenib and tolvaptan
| Article | Year |
|---|---|
Targeting B-Raf as a treatment strategy for polycystic kidney disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Benzenesulfonates; Cell Proliferation; Cells, Cultured; Humans; Niacinamide; Phenylurea Compounds; Polycystic Kidney Diseases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Tolvaptan | 2010 |